# Effects of occlusal disharmony on susceptibility to atrial fibrillation in mice

Kenji Suita <sup>a</sup>, Yuka Yagisawa <sup>b</sup>, Yoshiki Ohnuki <sup>a</sup>, Daisuke Umeki <sup>b</sup>, Megumi Nariyama <sup>c</sup>, Aiko Ito <sup>b</sup>, Yoshio Hayakawa <sup>e</sup>, Ichiro Matsuo <sup>d</sup>, Yasumasa Mototani <sup>a</sup>, Yasutake Saeki <sup>a</sup>, Satoshi Okumura <sup>a, \*</sup>

<sup>a</sup> Department of Physiology; <sup>b</sup> Department of Orthodontics; <sup>c</sup> Department of Pediatric dentistry; <sup>d</sup> Department of Periodontology; <sup>e</sup> Department of Anesthesiology, Tsurumi University School of Dental Medicine, Yokohama 230-8501, Japan.

# **Supplementary Figures**



**Supplementary Figure 1.** The original photo of Fig. 1A. The black-line box indicated by the arrow corresponds to the cropped part that is shown in the main article.



**Supplementary Figure 2.** Representative full-length immunoblots of Fig. 4C. The amounts of phosphorylated CaMKII at Thr-286 (left panel) and total CaMKII (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 3.** Representative full-length immunoblots of Fig. 4C. The amounts of oxidized CaMKII at Met-281/282 (left panel) and total CaMKII (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 4.** Representative full-length immunoblots of Fig. 4C. The amounts of phosphorylated RyR2 at Ser-2814 (left panel) and total RyR2 (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 5.** Representative full-length immunoblots of Fig. 4D. The amounts of Bax (left panel) and total Bcl-2 (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 6.** Representative full-length immunoblots of Fig. 4E. The amounts of activated caspase 9 (left panel) and GAPDH (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 7.** Representative full-length immunoblots of Fig. 4F. The amounts of activated caspase 3 (left panel) and GAPDH (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.



**Supplementary Figure 8.** Representative full-length immunoblots of Fig. 4G. The amounts of phosphorylated Akt at Ser-473 (left panel) and total Akt (right panel) are shown. The black-line box indicated by the arrow in each blot corresponds to the cropped parts that are shown in the main article. C: control, B: BO, PB: Propranolol + BO, D: dummy sample.